Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

BMS 493 has been used:as an inhibitor for the dietary and pharmacologic manipulation of retinoic acid (RA) activity in vivo and in vitrofor human induced pluripotent stem cells (iPSCs) culture and ventricular cardiomyocytes (VCMs) differentiationto inhibit retinoic acid (RA) signaling in explantsas a retinoic acid receptor (RAR) inhibitor for the induction of synaptonemal complex protein 3 (SCP3) and ATP-dependent RNA helicase (DDX4) in primordial germ cells (PGCs)

Biochem/physiol Actions

BMS 493 is an inverse pan-RAR agonist. Retinoic acid receptors (RARs) are ligand-dependent transcription factors that control a number of physiological processes. RARs exert their functions by regulating gene networks controlling cell growth, differentiation, survival, and death.

Features and Benefits

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Nuclear Receptors (Non-Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

General description

BMS 493 inhibits the formation of neuritic processes and plasmenyethanolamine -phospholipase A2 (PLA2) activity.

Packaging

5, 25 mg in glass bottle